Background and Aim
Results
CHB patients were classified into treatment-naïve patients with low HBV DNA titer (CHB-L; n = 28), high HBV DNA titer (CHB-H; n = 24) by the cut-off level of serum HBV DNA 4 log copies/ml, and patients receiving nucleos(t)ide analogue (CHB-NA; n = 19). The expressions of NKp46 and NKG2A were higher in CHB-H than in HS/CHB-L/CHB-NA. HepG2.2.15 had higher NKp46-ligand expression than HepG2. When NK cells from HS were co-cultured with HepG2.2.15, inhibition of the NKp46 and NKp46-ligand interaction by anti-NKp46 antibody significantly reduced cytolysis of HepG2.2.15 and IFN-γ production. However, those reductions were not observed in co-culture with HepG2. Additionally, NK cells that highly expressed NKp46 also highly expressed NKG2A (NKp46 
Introduction
Hepatitis B virus (HBV) infection is a critical cause of liver cirrhosis and hepatocellular carcinoma. HBV has spread worldwide and is a global health problem. The population of patients with HBV infection is estimated at over 300 million [1, 2] . Innate immunity, including natural killer (NK) cells, plays an important role in the control of viral infection [3, 4] . NK cells attack and eradicate infected cells directly in a major histocompatibility complex (MHC)-independent manner [5] . NK cells also play a role in bridging adaptive immunity by producing IFN-γ [6] . In contrast, a previous study demonstrated that activated NK cells suppress HBV-specific CD8 + T cells in the human liver, which led to persistent HBV infection by negatively regulating host immunity [7] . Thus, the role of NK cells in HBV infection remains controversial. The activation of NK cells is controlled by NK cell receptors. Recently, various NK cell receptors were identified and classified into activating and inhibitory receptors [3, 8] . The expressions of NK cell receptors in patients with HBV infection were comprehensively analyzed in several previous reports [9] [10] [11] [12] [13] [14] . In regards to activating NK cell receptors, the expression of NKp46 was higher in patients with HBV infection than in healthy control, while the expression of other activating receptors, such as NKp30, NKp44, NKG2C and NKG2D, were not different [12] . NKp46 is a transmembrane glycoprotein [15] and specific NK cell receptor that raises MHC non-restrictive cytotoxicity [16] . The expression of NKp46 is positively correlated with cytotoxicity [17, 18] and plays an important role in eliminating viral infected cells by recognizing viral proteins [19, 20] .
In regards to inhibitory NK cell receptors, the expression of NKG2A was lower in patients with HBV infection than in those without HBV infection, while the expression of other inhibitory receptors, such as KIR2DL1/DS1(CD158a/h) and KIR2DL2/DL3 (CD158b), were not different [13] . NKG2A is a major and prominent inhibitory NK cell receptor and is known as lectin superfamily group A [21] . We previously reported that inhibition of NKG2A restored the activity of NK cells from patients with hepatitis C virus (HCV) infection [22] . The expression of NKG2A was associated with clearance of HCV and HBV [23, 24] . These suggest that both NKp46 and NKG2A play important roles in the pathogenesis of viral hepatitis. However, the significance of the expression of NKp46 and NKG2A in HBV patients still remains controversial [9] [10] [11] [12] [13] [14] . The roles of NKp46 and NKG2A have not been elucidated in chronic hepatitis B (CHB) and the significance of NK cells co-expression of NKp46 and NKG2A remains unknown.
In this study, we investigated the involvement of NK cell receptors, focusing on NKp46 and NKG2A in the pathogenesis of HBV infection. We evaluated the expression of these receptors and their ligands in CHB patients. Additionally, NK cells with high NKp46 expression also highly expressed NKG2A (NKp46   high   NKG2A high subset) and exhibited higher cytotoxicity and lower IFN-γ production than the other NK cell subset. The frequency of this novel subset was positively correlated with serum ALT and HBV DNA levels. The results of this study improve our understanding of the mechanisms of liver injury and HBV replication.
Patients and methods

Study subjects
This study was approved by the Institutional Review Board for Clinical Research at Osaka University Hospital (No. 12238-2) and performed in accordance with the Declaration of Helsinki. Inclusion criteria for this study were age over 20-year-old, absence of known cancer and written informed consent. Seventy-one CHB patients and 37 healthy subjects (HS) were enrolled. The patients with HCV infection were excluded. The CHB patients were divided into 3 groups, treatment-naïve patients with low HBV DNA titer (CHB-L; n = 28), those with high HBV DNA titer (CHB-H; n = 24) and patients receiving nucleos(t)ide analogue (NA) treatment over 24 weeks (CHB-NA: n = 19, 18 with entecavir and 1 with lamivudine/adefovir). The serum HBV DNA levels were assessed by real-time quantitative polymerase chain reaction (TaqMan-PCR) assay. The serum HBV DNA cut-off between CHB-L and CHB-H was 4 log copies/ml. CHB-H were younger and consisted of more HBeAg-positive patients than CHB-L ( Table 1 ). All CHB patients and HS provided written informed consent before enrollment. The clinical data from these participants were given new numbers and anonymized before analysis. All data were provided separately as Supporting Information (S1 Data).
Flow cytometry analysis
Peripheral blood mononuclear cells (PBMC) were isolated using lymphocyte separation solution (Nacalai Tesque, Kyoto, Japan To examine the cytolysis of NK cells against these target cell lines, a redirected killing assay was performed. NK cells were co-cultured with the target cell lines labeled with carboxyfluorescein succinimidyl ester (CFSE, V12883; Invitrogen, Carlsbad, CA). After incubation for 4 hours, peridinin chlorophyll protein (PerCP) conjugated anti-7-aminoactinomycin D (7-AAD) antibody (420404; BioLegend, San Diego, CA) was added prior to flow cytometry analysis. The rate of specific lysis of target cells was determined as the number of 7AAD + CFSE + cells/number of CFSE + cells. The IFN-γ production in the supernatant was evaluated using enzyme-linked immunosorbent assay (ELISA) with a human IFN-γ Quantikine kit (DIF50; R&D systems). Anti-NKp46 neutralizing antibody (5 μl/ml, 9E2; BioLegend) or isotype human IgG1 were added to inhibit NKp46 and NKp46-ligand interaction.
NKp46-ligand detection in vitro
To detect NKp46-ligand in HepG2 and HepG2.2.15, we used human chimeric antibody, which is fused human NKp46 and Fc region of human IgG1 (1850-NK-025; R&D systems). HepG2 and HepG2.2.15 were incubated with this chimeric antibody for 2 hours. For the secondary antibody, these cells were stained with APC conjugated anti-human IgG1 antibody (97924; R&D systems) for 30 minutes and analyzed by flow cytometry. As negative control, unlabeled human IgG1 (Eureka therapeutics, Emeryville, CA) was used instead of chimeric protein.
We also examined the expression of NKp46-ligand in Huh6 and HB611 cell line, kindly provided by K. Ueda (Department of Microbiology, Osaka University Graduate School of Medicine, Suita, Japan). HB611 was established through transfection of HBV genome DNA into the human hepatoma cell line Huh6 and continuously replicates HBV DNA [27] .
Cell sorting and real-time PCR
From freshly isolated PBMC, NK cells were magnetically sorted using a MACS kit (130-092-657, Miltenyi Biotec, Bergisch Gladbach, Germany) according to its instruction. Specific NK cell subsets were electrically sorted using a FACS Aria cell sorter (BD Bioscience). The total RNA was extracted using a RNA micro kit (QIAGEN, Hilden, Germany). From these RNA, complementary DNA were synthesized using reverse transcriptase and ReverTra Ace qPCR Master mix (Toyobo, Osaka, Japan). TaqMan gene expression assays (Applied Biosystems, Foster City, CA) were performed for the following factors: human TRAIL (Assay ID; Hs00366278_m1), Fas ligand (Hs00181225_m1), signal transducer and activator of transcription (STAT)1 (Hs01013996_m1), IFN-γ (Hs00989291_m1) and β-actin (Hs99999903_m1). All of these target gene expression levels were normalized to the human β-actin expression levels.
Degranulation and intracellular cytokine staining of NK cells
To examine the function of NK cells, isolated PBMC were co-cultured with or without K562, an NK cell-sensitive cell line, at an effector-to-target (E/T) ratio of 1:1. FITC conjugated anti-human CD107a monoclonal antibody (H4A3; BioLegend) was added at the time of co-culture to assess degranulation. After co-culturing for 1 hour, Golgi stop solution (1 μl/ml; BD Bioscience) was added and the cultures were incubated for 4 hours. Then, a fixation/permeabilization solution (554714, 100 μl/sample, BD Bioscience) was added. After fixation, the samples were stained with PE conjugated anti-human IFN-γ monoclonal antibody (25723.11; BD Bioscience), CD56, CD3, NKp46 and NKG2A antibody and analyzed using flow cytometry.
Statistical analysis
The data are provided as the mean ± SEM or box-and-whisker plots unless otherwise indicated. An unpaired Student's t-test, the Mann-Whitney U test, a 1-way ANOVA or the Kruskal-Wallis test were applied using JMP software (ver. 10.0.2, SAS Institute Inc., Cary, NC). A two-sided P value <0.05 was considered statistically significant.
Results
The frequencies of NK cells and the expressions of NKp46 and NKG2A in HS, CHB-L, CHB-H and CHB-NA
We assessed the proportion of NK cells to lymphocytes in 37 HS, 28 CHB-L, 24 CHB-H and 19 CHB-NA using flow cytometry. CHB-H showed a lower frequency of NK cells than HS, CHB-L and CHB-NA (HS/CHB-L/CHB-H/CHB-NA: 12.7 ± 7.2%/11.1 ± 4.6%/8.2 ± 4.0%/ 11.1 ±4.3%) (Fig 1A) . NK cells were classified into CD56 dim and CD56 bright subsets according to previous reports [28, 29] . CHB-H showed a lower frequency of CD56 dim NK cells than HS, CHB-L and CHB-NA (HS/CHB-L/CHB-H/CHB-NA: 11.9 ± 6.9%/10.4 ± 4.4%/7.4 ± 3.9%) (Fig 1A) . There was no significant difference in the frequencies of CD56 bright NK cells among HS, CHB-L, CHB-H and CHB-NA (HS/CHB-L/CHB-H/CHB-NA: 0.75 ± 0.28%/ 0.68 ± 0.21%/0.74 ± 0.30%/0.78 ± 0.28%) ( Fig 1A) . Next, we analyzed the expression of NKp46 and NKG2A in NK cells. The expression of NKp46 was higher in CHB-H than in HS, CHB-L and CHB-NA (HS/CHB-L/CHB-H/CHB-NA: 22.5 ± 6.5/22.3 ± 6.6/31.7 ± 9.5/24.9 ± 7.1) ( Fig  1B) . The expression of NKG2A was higher in CHB-H than in HS, CHB-L and CHB-NA (HS/ CHB-L/CHB-H/CHB-NA: 96.4 ± 54.3/86.7 ± 38.5/127.2 ± 58.7/93.7 ±40.7) (Fig 1C) . Among these 4 groups, CD56 bright NK cells displayed higher expression of NKp46 and NKG2A than CD56 dim NK cells (S1 Fig). The expression of NKp46 was positively correlated with that of NKG2A, in treatment-naïve CHB patients (n = 52) (Fig 1D) (Fig 2A) . These results were compatible with functional dichotomy of NK cells, featuring retained or enhanced cytotoxicity and dysfunctional cytokine production by HBV infection [9, 31] . Functional dichotomy of NK cells in viral hepatitis was caused by two different signaling, phosphorylated STAT1 (pSTAT1) related to cytotoxicity and phosphorylated STAT4 (pSTAT4) related to cytokine production. In this co-culture assay, NK cells co-cultured with HepG2.2.15 showed higher expression of pSTAT1 and lower expression of pSTAT4 than those with HepG2 ( S3 Fig) . Flow cytometric analysis using chimeric antibody fused NKp46 and Fc region of human IgG1, the expression of NKp46-ligand was higher in HepG2.2.15 than in HepG2 (Fig 2B) . When we co-cultured NK cells from HS with HepG2.2.15, the addition of neutralizing antibody against NKp46 (Anti-NKp46 antibody) significantly reduced the cytolysis of HepG2.2.15 and IFN-γ production. However, those reductions were not observed in co-culture with HepG2 ( Fig 2C) . Additionally, we examined the expression of NKp46-ligand in other HBV infection model. high subset than those in the other subset (Fig 4A) .
In functional analysis by co-culturing with K562, the expressions of CD107a in the NKp46 high NKG2A high subset were higher than those in the other subset in both HS and CHB patients. In contrast, the expression of IFN-γ in the NKp46 high NKG2A high subset was lower than that in the other subset (Fig 4B) . (Fig 4C) .
Discussion
In the present study, we evaluated the frequency and role of NK cells that affect host innate immunity. We assessed the expression of NKp46 and NKp46-ligand in HBV infection and evaluated the role of NK cells, with a focus on a novel NK cell subset, the NKp46 high NKG2A high subset. Previous studies have reported the relationship between HBV infection and the expression of various NK cell receptors. Consistent with some studies [10, 12, 13, 24] but in contrast to others [9, 11, 14] , we demonstrated that the expression of NKp46 and NKG2A were high in CHB-H. However, few articles have evaluated the balance between activating and inhibitory receptors in NK cells. In this study, multicolor staining on the same sample was performed and, in 52 treatment-naïve CHB patients, the expression of NKp46 was positively correlated with the expression of NKG2A. Our results that the expression of CD107a was higher in NKp46 bright NK cells than in NKp46 dim NK cells is compatible with the function of NKp46, as an activating receptor. In contrast, the expression of CD107a was higher in NKG2A-positive NK cells than in NKG2A-negative NK cells. These results seem to be incompatible with the function of NKG2A as an inhibitory receptor, however, previous studies reported that NKG2A protects overactivation of NK cells by recognizing human leukocyte antigen E as a ligand [34] . Positive correlation between the expression of NKp46 and NKG2A raise the possibility that the expression of NKG2A negatively regulate NKp46 expressing NK cells with high cytotoxicity. We showed that NKp46-ligand was expressed in HepG2.2.15 and HB611. The natural ligand of NKp46 is still unknown [19, 20, 35] , however, hemagglutinin in the influenza virus was identified as one of the ligands of NKp46 [35] . Therefore, according to previous studies, it is reasonable to assume that one of the mechanisms driving NKp46-ligand is viral infection [16, 36] . Recently, Golden-Mason et al. reported that HCV-infected hepatocytes expressed NKp46-ligand [37] . To the best of our knowledge, the present study is the first report showing NKp46-ligand expression in HBV infection model. Viral infection often leads upregulation of ligands triggering NK cell receptors and these transformation make infected cells highly susceptible to killing by NK cells [38] . We showed that the specific lysis by NK cells in co-culture with HepG2.2.15 was higher than that with HepG2, and inhibition of NKp46 by neutralizing antibody clearly reduced the cytolysis in co-culture with HepG2.2.15 but not in co-culture with HepG2. These results suggest that the interaction of NKp46 and NKp46-ligand was associated with NK cell activity in HBV infection. Previous reports showed that cytotoxicity was retained or over-activated, whereas the ability of IFN-γ production was hampered in NK cells from patients with viral hepatitis [9, [39] [40] [41] 
Conclusion
In the present study, we showed that NKp46 and NKp46-ligand expression were high on NK cells and hepatocytes in HBV infection, respectively. . NK cells were isolated from peripheral blood of healthy subjects using MACS kit (130-092-657, Miltenyi Biotec, Germany). These NK cells were co-cultured with HepG2 or HepG2.2.15 at effector to target ratio of 1;1. After co-culturing for 4 hours, NK cells were stained with CD3 and CD56 monoclonal antibody. After staining, methanol (100μl/well, 15 minutes) and a fixation/permeabilization solution (554714, BD Bioscience, 100μl/well, 15 minutes) were added. After fixation, the samples were stained with anti-human pSTAT1 and pSTAT4 monoclonal antibody and analyzed using flow cytometry.
Ã ; P <0.05. 
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